Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease

Yuan Hung Yeh, Po Hui Wang, Long Yau Lin, Yi Torng Tee, Ming Chih Chou, Shun Fa Yang, Hsiu Ting Tsai

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: To determine expression levels of urokinase-type plasminogen activator (uPA), soluble urokinase-type plasminogen activator receptor (suPAR), plasminogen activator inhibitor-1 (PAI-1) in plasma and to identify gene polymorphisms specific to patients with pelvic inflammatory disease (PID) and healthy controls. Methods: Enzyme-linked immunosorbent assay and polymerase chain reaction-restriction fragment length polymorphism were used to measure plasma levels and polymorphisms in uPA, suPAR, and PAI-1 among seventy healthy controls and 64 PID patients before and after they received routine treatment protocols. Results: The levels of plasma uPA (ng/ml) and soluble suPAR (pg/ml) were significantly increased in PID patients (uPA: 0.57 ± 0.03; suPAR: 1372.04 ± 68.20) when compared to that in normal controls (uPA: 0.55 ± 0.06, p = 0.002; suPAR: 1192.46 ± 51.98, p = 0.04); moreover, suPAR decreased significantly after treatment when compared to levels noted in the same patients (1220.06 ± 58.14; p = 0.003) after they received treatment. The increased expression of suPAR was significantly correlated with WBC counts (r = 0.382, p = 0.002, n = 64) in blood as well as the plasma levels of CRP (r = 0.441, p.

Original languageEnglish
Pages (from-to)138-144
Number of pages7
JournalClinica Chimica Acta
Volume415
DOIs
Publication statusPublished - Jan 16 2013
Externally publishedYes

Fingerprint

Urokinase Plasminogen Activator Receptors
Pelvic Inflammatory Disease
Blood
Urokinase-Type Plasminogen Activator
Polymorphism
Plasmas
Plasminogen Activator Inhibitor 1
Immunosorbents
Polymerase chain reaction
Clinical Protocols
Restriction Fragment Length Polymorphisms
Assays
Genes
Enzyme-Linked Immunosorbent Assay
Polymerase Chain Reaction
Enzymes
Therapeutics

Keywords

  • Pelvic inflammatory disease
  • Polymorphism
  • Soluble urokinase-type plasminogen activator receptor
  • Urokinase-type plasminogen activator

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease. / Yeh, Yuan Hung; Wang, Po Hui; Lin, Long Yau; Tee, Yi Torng; Chou, Ming Chih; Yang, Shun Fa; Tsai, Hsiu Ting.

In: Clinica Chimica Acta, Vol. 415, 16.01.2013, p. 138-144.

Research output: Contribution to journalArticle

Yeh, Yuan Hung ; Wang, Po Hui ; Lin, Long Yau ; Tee, Yi Torng ; Chou, Ming Chih ; Yang, Shun Fa ; Tsai, Hsiu Ting. / Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease. In: Clinica Chimica Acta. 2013 ; Vol. 415. pp. 138-144.
@article{7faa7b23104041728389deb09c1932e0,
title = "Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease",
abstract = "Background: To determine expression levels of urokinase-type plasminogen activator (uPA), soluble urokinase-type plasminogen activator receptor (suPAR), plasminogen activator inhibitor-1 (PAI-1) in plasma and to identify gene polymorphisms specific to patients with pelvic inflammatory disease (PID) and healthy controls. Methods: Enzyme-linked immunosorbent assay and polymerase chain reaction-restriction fragment length polymorphism were used to measure plasma levels and polymorphisms in uPA, suPAR, and PAI-1 among seventy healthy controls and 64 PID patients before and after they received routine treatment protocols. Results: The levels of plasma uPA (ng/ml) and soluble suPAR (pg/ml) were significantly increased in PID patients (uPA: 0.57 ± 0.03; suPAR: 1372.04 ± 68.20) when compared to that in normal controls (uPA: 0.55 ± 0.06, p = 0.002; suPAR: 1192.46 ± 51.98, p = 0.04); moreover, suPAR decreased significantly after treatment when compared to levels noted in the same patients (1220.06 ± 58.14; p = 0.003) after they received treatment. The increased expression of suPAR was significantly correlated with WBC counts (r = 0.382, p = 0.002, n = 64) in blood as well as the plasma levels of CRP (r = 0.441, p.",
keywords = "Pelvic inflammatory disease, Polymorphism, Soluble urokinase-type plasminogen activator receptor, Urokinase-type plasminogen activator",
author = "Yeh, {Yuan Hung} and Wang, {Po Hui} and Lin, {Long Yau} and Tee, {Yi Torng} and Chou, {Ming Chih} and Yang, {Shun Fa} and Tsai, {Hsiu Ting}",
year = "2013",
month = "1",
day = "16",
doi = "10.1016/j.cca.2012.10.038",
language = "English",
volume = "415",
pages = "138--144",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",

}

TY - JOUR

T1 - Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease

AU - Yeh, Yuan Hung

AU - Wang, Po Hui

AU - Lin, Long Yau

AU - Tee, Yi Torng

AU - Chou, Ming Chih

AU - Yang, Shun Fa

AU - Tsai, Hsiu Ting

PY - 2013/1/16

Y1 - 2013/1/16

N2 - Background: To determine expression levels of urokinase-type plasminogen activator (uPA), soluble urokinase-type plasminogen activator receptor (suPAR), plasminogen activator inhibitor-1 (PAI-1) in plasma and to identify gene polymorphisms specific to patients with pelvic inflammatory disease (PID) and healthy controls. Methods: Enzyme-linked immunosorbent assay and polymerase chain reaction-restriction fragment length polymorphism were used to measure plasma levels and polymorphisms in uPA, suPAR, and PAI-1 among seventy healthy controls and 64 PID patients before and after they received routine treatment protocols. Results: The levels of plasma uPA (ng/ml) and soluble suPAR (pg/ml) were significantly increased in PID patients (uPA: 0.57 ± 0.03; suPAR: 1372.04 ± 68.20) when compared to that in normal controls (uPA: 0.55 ± 0.06, p = 0.002; suPAR: 1192.46 ± 51.98, p = 0.04); moreover, suPAR decreased significantly after treatment when compared to levels noted in the same patients (1220.06 ± 58.14; p = 0.003) after they received treatment. The increased expression of suPAR was significantly correlated with WBC counts (r = 0.382, p = 0.002, n = 64) in blood as well as the plasma levels of CRP (r = 0.441, p.

AB - Background: To determine expression levels of urokinase-type plasminogen activator (uPA), soluble urokinase-type plasminogen activator receptor (suPAR), plasminogen activator inhibitor-1 (PAI-1) in plasma and to identify gene polymorphisms specific to patients with pelvic inflammatory disease (PID) and healthy controls. Methods: Enzyme-linked immunosorbent assay and polymerase chain reaction-restriction fragment length polymorphism were used to measure plasma levels and polymorphisms in uPA, suPAR, and PAI-1 among seventy healthy controls and 64 PID patients before and after they received routine treatment protocols. Results: The levels of plasma uPA (ng/ml) and soluble suPAR (pg/ml) were significantly increased in PID patients (uPA: 0.57 ± 0.03; suPAR: 1372.04 ± 68.20) when compared to that in normal controls (uPA: 0.55 ± 0.06, p = 0.002; suPAR: 1192.46 ± 51.98, p = 0.04); moreover, suPAR decreased significantly after treatment when compared to levels noted in the same patients (1220.06 ± 58.14; p = 0.003) after they received treatment. The increased expression of suPAR was significantly correlated with WBC counts (r = 0.382, p = 0.002, n = 64) in blood as well as the plasma levels of CRP (r = 0.441, p.

KW - Pelvic inflammatory disease

KW - Polymorphism

KW - Soluble urokinase-type plasminogen activator receptor

KW - Urokinase-type plasminogen activator

UR - http://www.scopus.com/inward/record.url?scp=84868645090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868645090&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2012.10.038

DO - 10.1016/j.cca.2012.10.038

M3 - Article

VL - 415

SP - 138

EP - 144

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

ER -